181 related articles for article (PubMed ID: 30707464)
21. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.
Strohmeier S; Brcic I; Popper H; Liegl-Atzwanger B; Lindenmann J; Brcic L
Sci Rep; 2021 May; 11(1):9785. PubMed ID: 33963267
[TBL] [Abstract][Full Text] [Related]
22. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
24. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
[TBL] [Abstract][Full Text] [Related]
25. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
[TBL] [Abstract][Full Text] [Related]
26. Primary NTRK-rearranged spindle cell neoplasm of bone harboring an HMBOX1::NTRK3 gene fusion.
Wang Z; Wang J
Genes Chromosomes Cancer; 2023 Aug; 62(8):477-482. PubMed ID: 36740981
[TBL] [Abstract][Full Text] [Related]
27. Detection of
Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
29. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
30. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
31. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry.
Arnold A; Daum S; von Winterfeld M; Berg E; Hummel M; Horst D; Rau B; Stein U; Treese C
Pathol Res Pract; 2019 Nov; 215(11):152662. PubMed ID: 31575452
[TBL] [Abstract][Full Text] [Related]
32. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.
Ye Q; Chen H; Han C; Peng Y; Huang X; Sun H; Wu Y; Albarracin CT; Middleton LP; Sahin AA; Huo L; Ding Q
J Clin Pathol; 2023 Aug; ():. PubMed ID: 37586834
[TBL] [Abstract][Full Text] [Related]
33. Detection of
Solomon JP; Hechtman JF
Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
[TBL] [Abstract][Full Text] [Related]
34. NTRK fusions and Trk proteins: what are they and how to test for them.
Weiss LM; Funari VA
Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
[TBL] [Abstract][Full Text] [Related]
35. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of two-step approach for screening NTRK fusion in two major subtypes of non-small cell lung cancer within a large cohort.
Dong K; Zhu Y; Liu X; Sun W; Yang X; Chi K; Jia L; Diao X; Huang X; Zhou L; Lin D
Hum Pathol; 2024 Jun; 149():39-47. PubMed ID: 38866255
[TBL] [Abstract][Full Text] [Related]
37. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
Kyker-Snowman K; Hughes RM; Yankaskas CL; Cravero K; Karthikeyan S; Button B; Waters I; Rosen DM; Dennison L; Hunter N; Donaldson J; Christenson ES; Konstantopoulos K; Hurley PJ; Croessmann S; Park BH
Breast Cancer Res Treat; 2020 Feb; 179(3):631-642. PubMed ID: 31823098
[TBL] [Abstract][Full Text] [Related]
38. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence
Fu Y; Li Z; Gao F; Yang J; Wu H; Zhang B; Pu X; Fan X
Front Oncol; 2021; 11():669197. PubMed ID: 33996597
[TBL] [Abstract][Full Text] [Related]
39. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
[TBL] [Abstract][Full Text] [Related]
40. Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
Karakas C; Giampoli EJ; Love T; Hicks DG; Velez MJ
Diagn Pathol; 2024 Jan; 19(1):10. PubMed ID: 38200576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
